ABSTRACT: Accumulating body of evidence incriminate Rho-kinase (ROCK) in the pathogenesis of pulmonary hypertension (PH). Therapeutic efficacy of azaindole-1, a novel highly selective and orally active ROCK inhibitor, has not yet been investigated in PH.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a chronic fatal disease characterized by sustained elevation of pulmonary artery pressure and reduced exercise tolerance. As a consequence the right ventricular (RV) afterload increases and culminates in RV failure. PAH has a complex pulmonary vascular pathophysiology including vasoconstriction, vascular remodeling and in situ thrombosis. The progressive vascular remodeling, the hallmark of PAH pathology, is attributable to abnormalities in vascular cells such as increased proliferation and resistance to apoptosis (1) (2) (3) . However, the precise molecular mechanism is incompletely understood, and the therapeutic approach to cure the disease is yet most desirable.
The small GTPase RhoA is one of the members of the Rho protein family that regulate cellular functions such as contraction, motility, proliferation and apoptosis, and Rho kinases (ROCKs) are the best characterized downstream targets for RhoA (4) . Two isoforms of the serine/threonine kinase ROCK have been identified: ROCK-1 and ROCK-2 (5-7). ROCKs are ubiquitously expressed in tissues including vasculature and heart. Due to its role in key cell functions a hyperactive ROCK signaling results in cardiovascular disorders associated with sustained abnormal vasoconstriction and promotion of vascular remodeling (8, 9) .
Studies on animal models of pulmonary hypertension (PH) such as chronic hypoxia-, monocrotaline (MCT)-, VEGF receptor inhibition and chronic hypoxia-, pneumonectomy and MCT-and bleomycin-induced PH suggest that increased ROCK is involved in the pathogenesis (10) (11) (12) (13) (14) (15) (16) . Moreover, data are emerging that implicate ROCK signaling in clinical PH and that Rho kinase inhibition provides beneficial acute effects in patients (17) (18) (19) (20) (21) (22) (23) .
Fasudil and Y-27632 are the two most commonly investigated ROCK inhibitors (24, 25) .
Fasudil has been approved for human use in Japan for the treatment of cerebral vasospasm after subarachnoid hemorrhage and is also a relatively potent inhibitor of other kinases such as protein kinase C (26, 27) . These inhibitors have been instrumental in elucidating the role of ROCK in the pathobiology of PH. The ROCK inhibitors show beneficial effects on rodent models of PH; however, discrepancy in their efficacy has also been observed depending on the dose, route of administration and animal model (9) . Recently, a highly selective and orally active azaindole-based ROCK inhibitor has been reported (28, 29) . This novel ROCK inhibitor, azaindole-1 functions in ATP-competitive manner with activity in the low nanomolar range (IC50 of 0.6nM and 1.1nM for human ROCK1 and ROCK2, respectively).
Moreover, oral administration of azaindole-1 induces a dose-dependent decrease in blood pressure without inducing a significant reflex increase in heart rate of normotensive and spontaneously hypertensive rats (28) . However, the therapeutic potential of azaindole-1 in animal models of PH has not yet been explored. In this study, we have therefore investigated the effects of azaindole-1 on 1) acute hypoxic pulmonary vasoconstriction (HPV) in isolated, ventilated and buffer-perfused murine lungs and proliferation of rat PASMC in vitro, 2) hemodynamics, right ventricular hypertrophy and pulmonary vascular remodeling in experimental PH induced by monocrotaline injection in rats and by chronic hypoxic exposure in mice, 3) ROCK activity and pulmonary vascular cell proliferation by immunohistochemistry of the lung tissues of monocrotaline-injected rats for phospho-myosin phosphatase target subunit 1 (p-MYPT1) and proliferating cell nuclear antigen (PCNA).
METHODS

Animals
Adult male Sprague-Dawley rats (300-350 g BW) and C57BL/6 mice (20-22 g BW) were obtained from Charles River Laboratories, Sulzfeld, Germany. Pulmonary hypertension (PH) was induced in rats by monocrotaline (Sigma-Aldrich) injection and in mice by exposing to chronic hypoxia (10%) as described (30) . All studies were performed according to the guidelines of the University of Giessen and were approved by the local authorities (Regierungs praesidium Giessen, GI20/10-Nr.48/2009; GI 20/10 Nr.39/2009).
Experimental design
Radio-telemetry study
Monocrotaline-injected rats (MCT-rats) were randomized into two groups and they received either azaindole-1 (Bayer Health Care AG) or placebo from day 21 for two weeks.
Azaindole-1 was prepared daily in transcutol-based vehicle as described (28) and rats were treated by oral gavage at the dose of 10 mg/kg BW/day. The placebo group received only vehicle. The dose of azaindole-1 was selected based on literature (28) and our own pilot experiments (data not shown). The right ventricular systolic pressure (RVSP) and heart rate (HR) were monitored online with an implanted radio-telemetry system (Dataquest A.R.T.
2.1; Data Sciences Inc.) as described (30) . Briefly, a catheter connected to a fluid filled sensor was inserted into the jugular vein and forwarded to the RV of rats under anaesthesia.
The signal from the transmitter (model TA11PA-C40) was transferred to a remote receiver and a data-exchange matrix connected to a computer. The waveform was displayed on the computer and used to ensure correct positioning of the catheter. Animals were allowed to recover and were housed individually in standard rat cages. RVSP and HR were recorded once per day over the next 35 days from the time of MCT-injection.
Chronic treatment study
To investigate the therapeutic efficacy of azaindole-1 in animal models of PH, chronic treatment studies were performed. The MCT-rats were randomized into two groups and treated orally by gavage from 21 to 35 days either with azaindole-1 (10mg/kg BW/day) or placebo. Saline injected rats served as healthy control. Mice exposed to chronic hypoxia 5 were treated daily with azaindole-1 (30mg/kg BW/day) or placebo from 21 to 35 days. As mentioned, the dose of azaindole-1 was selected based on literature (28) and our own pilot experiments (data not shown) and prepared daily for oral application. Control mice remained under normoxia (21% O2). At the end of experiment (day 35 of the MCT-injection in rats or chronic hypoxic exposure of mice) the animals were sacrificed for hemodynamic and right ventricular hypertrophy measurements.
Hemodynamic and right ventricular hypertrophy (RVH) measurements
RVSP was measured by a catheter inserted into the RV via the right jugular vein, and for systemic arterial pressure (SAP) the left carotid artery cannulation was performed as described (30) . Cardiac output was calculated using the Fick principle, by employing the mixed venous oxygen and the arterial oxygen content as previously described (31) . The total pulmonary and systemic vascular resistance indexed to body weight (TPR and TSR respectively) were determined as reported (32) . The heart was dissected to separate right ventricle (RV) from left ventricle plus septum (LV+S), and the ratio RV/(LV+S) was calculated as a measurement for RVH.
Histology and pulmonary vascular morphometry
Lung tissue preparation, sectioning, staining and vascular morphometry were done as described (33) . Intra-acinar arteries in rats and mice were analyzed by categorizing them as fully muscular, partially muscular and non-muscular. In addition, the medial wall thickness of the vessels was analyzed. All analyses were done in a blinded fashion.
Immunohistochemistry for phospho-myosin phosphatase target subunit 1 (p-MYPT1) and proliferating cell nuclear antigen (PCNA) Paraffin-embedded lung tissue sections with thickness of 3 µm were deparaffinized in xylene and rehydrated in a graded ethanol series to phosphate-buffered saline (PBS, pH 7.4).
Antigen retrieval was performed by pressure cooking in citrate buffer (pH 6.0). The sections were pretreated with hydrogen peroxide (15%) to quench endogenous peroxidase activity. 
Isolated murine lungs
The technique of successive hypoxic maneuvers was employed in isolated, ventilated and buffer-perfused mice lungs to investigate the effect of azaindole-1, fasudil (H139, Sigma) and Y-27632 (Y0503, Sigma) on acute hypoxic pulmonary vasoconstriction (HPV) as described (34) . The ROCK inhibitors were prepared in dimethyl sulfoxide (DMSO). Sequential hypoxic maneuvers of 10 min duration interrupted by 15 min periods of normoxia were performed. The effect of the rho-kinase inhibitors on pressure responses provoked by alveolar hypoxia (1% O2) was determined within such a sequence of repetitive hypoxic maneuvers.
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The rho-kinase inhibitors were added to the buffer fluid 5 min after a hypoxic challenge, with the addition starting after the second hypoxic maneuver was accomplished. Cumulative doseeffect curves were established by addition of the inhibitors (dose range: 0.1-30.0 µM).
Controls received the vehicle (DMSO) only.
MTT and thymidine incorporation assays
The isolation, culture and proliferation assay of primary pulmonary artery smooth muscle cells (PASMCs) were done as described previously (33) . Briefly, cells were isolated from healthy and monocrotaline-injected rats (day 21, n = 3) and cultures were maintained at 37°C 
RESULTS
Effects of azaindole-1 on acute hypoxic pulmonary vasoconstriction (HPV)
The induced any reflex tachycardia, we monitored the heart rate of the rats. We observed that the heart rates of placebo and azaindole-1 treated rats were comparable (Figure 2b ). The findings suggest that azaindole-1 has potent pulmonary vasorelaxant effect in vivo.
Effects of azaindole-1 on hemodynamics in MCT-and chronic hypoxia-induced PH
We investigated therapeutic efficacy of azaindole-1 in two independent animal models of PH (Figure 3b ). There was no significant change in systemic arterial pressure (SAP) and total systemic resistance (TSR) among the experimental groups (Figures 3c, 3d ).
In addition, analysis of cardiac output showed a comparable cardiac index (CI) among the experimental groups (24.9 ± 4.2, 23.8 ± 1.9 and 28.8 ± 3. 
Effects of azaindole-1 on vascular remodeling in MCT-and chronic hypoxia-induced PH
The effects of azaindole-1 on pulmonary vascular remodeling were assessed by determining the degree of muscularization and medial wall thickness of the peripheral pulmonary arteries.
MCT injection in rats and chronic hypoxia in mice resulted in an enhanced pulmonary artery muscularization as evident from the enhanced immunoreactivity for α-SMC actin (Figures   6a, 7a ). Pulmonary vascular morphometry revealed significantly increased fully muscularized vessels (57.0 ± 1.5 %) and decreased non-muscularized vessels (2.4 ± 0.3 %) in MCTinjected rats receiving placebo as compared to healthy control (2.2 ± 0.8 and 42.2 ± 3.7 % respectively). Azaindole-1 treatment significantly decreased fully muscularized vessels (18.5 ± 2.4 %) (Figure 6b ). There was significantly higher proportion of partially muscularized vessels in azaindole-1 treated rats (73.3 ± 2.2 versus 40.6 ± 1.4 % in placebo), suggesting that the treatment impaired the progressive muscularization by preventing the shift from partial towards full muscularization of the vessels. Moreover, we measured the medial wall thickness of the same size vessels. There was significantly increased medial wall thickness in placebo (22.3 ± 0.9 versus 9.7 ± 0.4 % in healthy control). Corroborating the decreased fully muscularized vessels, azaindole-1 significantly reduced the medial wall thickness (14.0 ± 0.6 %) (Figure 6c, 6d) .
In chronic hypoxic mice, the non-muscularized vessels were significantly decreased (4.9 ± 1.5 versus 49.3 ± 1.3 % in normoxic mice), whereas the partially and fully muscularized vessels were significantly increased (63.5 ± 4.7 and 31.5 ± 3.9 % versus 47.3 ± 0.5 and 3.5 ± 1.3 % in normoxic mice, respectively). Treatment with azaindole-1 resulted in significant reduction of fully muscularized vessels (7.5 ± 1.7 %) ( Figure 7b ). As was observed in MCTinjected rats, the proportion of partially muscularized arteries was higher in mice receiving azaindole-1 (80.9 ± 2.9 %). Chronic hypoxia resulted in significantly increased medial wall thickness (17.8 ± 0.9 %) as compared to the normoxic control mice (10.1 ± 0.3 %) (Figure 7c,   7d ). Corroborating the decreased fully muscularized vessels, the medial wall thickness was significantly reduced in azaindole-1 treated mice (12.4 ± 0.4 %) (Figure 7d ).
Effects of azaindole-1 on ROCK activity and pulmonary vascular cell proliferation
We investigated the effects of azaindole-1 on ROCK activity by employing immunohistochemistry for the phospho-myosin phosphatase target subunit 1 (p-MYPT1).
The immunoreactivity was localized in the media of the vessels and was enhanced in the lung tissues of MCT-rats receiving placebo. There was decreased immunoreactivity in MCT-rats treated with azaindole-1 (Figure 8a ).
To confirm if the effect of azaindole-1 on cell proliferation as was observed in vitro was also present in vivo, we performed immunostaining for proliferating cell nuclear antigen (PCNA).
We observed that immunoreactivity for PCNA was significantly increased in lung tissues from MCT-injected rats as compared to that in healthy control rats (Figure 8b ). We analyzed the same size vessels as was used for vascular morphometry to quantify the PCNA positive 13 vascular cells and expressed as index of proliferation (IOP). The findings revealed that there was higher IOP in MCT-rats receiving placebo (431.9 ± 7.2 versus 100.0 ± 25.8 % in healthy control rats) (Figure 8b ). Corroborating the in vitro data, the IOP was significantly reduced in MCT-rats receiving azaindole-1 (184.1 ± 10.9 %) (Figure 8c ). and thus in reduced pulmonary arterial pressure (14, 16, 39) . In this line, we observed that azaindole-1 significantly impaired the monocrotaline induced progressive elevation of RVSP in rats as monitored online by radio-telemetry technique. However, no significant effect was observed on heart rates, suggesting that azaindole-1 treatment did not result in reflex tachycardia. Our finding is in agreement with the studies that describe the involvement of ROCK-mediated sustained vasoconstriction in the PH pathogenesis (14, 39-41). Moreover, as inhibition of ROCK has been shown to impair pulmonary vascular remodeling (10, 42-44),
DISCUSSION
we sought to test the response of proliferating PASMC to azaindole-1 in vitro. We observed that azaindole-1 significantly inhibited the thymidine incorporation into the primary rat PASMC at high nanomolar to low micromolar range, and the effect was more potent than fasudil and Y-27632. Taken together, the findings of our in vivo, ex vivo and in vitro studies attribute potent vasorelaxant and antiproliferative properties to azaindole-1 and thus substantiate its therapeutic potential in PH.
We therefore performed the chronic treatment studies and investigated the therapeutic efficacy of azaindole-1 in experimental PH induced by monocrotaline injection in rats and by chronic hypoxia in mice. We found that azaindole-1 improved PH, right ventricular hypertrophy (RVH) and pulmonary vascular remodeling as evident from significantly reduced RVSP, TPR, RV/(LV+S) and muscularization and medial wall thickness of peripheral pulmonary vessels. Moreover, the systemic arterial pressure did not change significantly in the treated animals. Although at first glance it seems contradictory to the findings by Kast et al., who observed reduction of blood pressure in spontaneously hypertensive (SH) rats receiving azaindole-1 (28). However, the discrepancy could be explained at least in part by the differences in animal models and duration of treatment. In SH rats the ROCK activity is enhanced in systemic vasculature (45); furthermore, Kast et al treated the normotensive rats only once and SH rats for 4 days and noted in the SH rats that the blood pressure lowering effect was gradually decreasing. In the current study, we used different animal models of PH and treated the animals for two weeks. Our data therefore may not be directly comparable to that of Kast et al. Notably, the sustained pulmonary ROCK activation in animal models of PH (9) can thus be anticipated to yield therapeutic benefit; however, studies are warranted to investigate if the antiproliferative and vasorelaxant potency of azaindole-1 is adequate to improve the severely remodeled pulmonary vessels with occlusive lesion that is commonly observed in human PH. Regarding human PH, literature is emerging that implicates Rho kinase signaling in the disease pathogenesis and thus this signaling pathway represents a potential therapeutic target (17, 19, 21, 23) . Moreover, acute inhibition of ROCK by fasudil has revealed beneficial effects as evident from reduction of pulmonary vascular resistance and pulmonary arterial pressure in patients with severe PH (17, 18, 20, 22) . The data thus support that inhibition of Rho kinase with a potent and highly selective inhibitor may offer a potential therapeutic strategy.
In summary, we demonstrate that daily oral application of azaindole-1 improves the hemodynamics, right ventricular hypertrophy and pulmonary vascular remodeling in experimental PH. This study, to our knowledge, is the first to investigate the therapeutic efficacy of a novel potent and orally available ROCK inhibitor azaindole-1 in two independent animal models of PH. Moreover, we show that azaindole-1 potently inhibits the hypoxic pulmonary vasoconstriction in isolated, ventilated and buffer-perfused murine lungs, significantly inhibits proliferation of primary rat PASMC in vitro and reduces the number of proliferating pulmonary vascular cells in MCT-injected rats, suggesting that the therapeutic benefit of azaindole-1 may be associated with its vasorelaxant and antiproliferative potency.
Taken together, the findings suggest that azaindole-1 may represent a novel therapeutic approach for the treatment of pulmonary hypertension.
Reference List The effects of azaindole-1 on progressive increase of RVSP induced by MCT injection in rats were investigated by radio-telemetry technique and RVSP and heart rate (HR) were monitored online as described in methods. (a) RVSP and (b) HR are given. Each dot represents mean ± SEM (n=6). *p<0.05, **p<0.01 and ***p<0.001. Rats were injected with saline (healthy control) or MCT. Mice were exposed to normoxia (Nox) and chronic hypoxia (Hox). The MCT-injected rats and hypoxic mice were treated with azaindole-1 or placebo from day 21 for 2 weeks followed by hemodynamic and right ventricular hypertrophy measurements at day 35 as described in methods. Right to left ventricular plus septum weight ratio [RV/(LV+S)] of (a) MCT-rats (n = 10-15) and (b) hypoxic mice (n = 6-10) are given. Each bar represents Mean ± SEM. *p<0.05, ***p<0.001.
Figure 6. Effect of azaindole-1 on vascular remodeling in MCT-induced PH.
The rat lung sections were immunostained for von Willebrand factor and α-smooth muscle actin and pulmonary vascular morphometry was performed as described in methods. The lung sections exposed to normoxia and hypoxia were immunostained for von Willebrand factor and α-smooth muscle actin followed by pulmonary vascular morphometry as Bars represent mean ± SEM (n= 6-10). ***p<0.001, scale = 20μm.
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Figure 8. Effects of azaindole-1 on ROCK activity and pulmonary vascular cell proliferation
The ROCK activity and pulmonary vascular cell proliferation were investigated in the rat lung sections by immunostaining p-MYPT1and PCNA respectively as described in methods.
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